that all external partners are qualified, contracted, and monitored effectively, and that sponsor accountability under ICH GCP is maintained. The SOP provides guidance on vendor selection, audits, risk assessments, performance monitoring, CAPA management, and documentation for inspection readiness.

Scope

This SOP applies to all vendors and CROs providing services in clinical trials, including data management, monitoring, pharmacovigilance, laboratory testing, logistics, and eClinical systems. It covers vendor qualification, contracts, governance frameworks, routine oversight, audits, escalation, and performance reporting across global jurisdictions (FDA, EMA, CDSCO, WHO).

Responsibilities

• Sponsor: Retains ultimate responsibility for vendor and CRO activities.
• Clinical Operations Manager: Implements vendor oversight framework and monitors performance.
• QA Officer: Conducts audits and reviews CAPA implementation.
• Procurement Department: Ensures contracts include regulatory compliance clauses.
• Vendor Manager: Coordinates vendor governance meetings and tracks KPIs.
• PI/Site: Ensures site-level compliance when vendors interface directly with trial sites.

Accountability

The sponsor is accountable for ensuring all vendors and CROs operate in compliance with ICH GCP, applicable regulations, and contractual obligations. QA ensures independent oversight, while vendor managers ensure continuous governance and monitoring.

Procedure

1. Vendor/CRO Qualification
Conduct vendor pre-qualification using questionnaires and capability assessments.
Verify licenses, certifications (ISO, CAP, GLP), and prior inspection history.
Document qualification results in Vendor Qualification Log (Annexure-1).

2. Contracting
Contracts must include scope of work, timelines, confidentiality, data protection, compliance with GCP, and audit rights.
Ensure Service Level Agreements (SLAs) and Key Performance Indicators (KPIs) are clearly defined.
File signed contracts in TMF/Procurement repository.

3. Vendor Oversight Framework
Establish Vendor Oversight Plan (Annexure-2) covering communication frequency, reporting structure, and review cycles.
Assign sponsor contact for each vendor.
Conduct governance meetings at defined intervals (quarterly or bi-annual).

4. Routine Monitoring
Review vendor deliverables (e.g., monitoring reports, data listings, safety reports).
Track vendor KPIs such as timeliness, quality, and compliance rates.
Document performance evaluations in Vendor Performance Log (Annexure-3).

5. Audits and Inspections
Conduct vendor audits annually or based on risk profile.
Verify compliance with SOPs, contracts, and regulatory requirements.
Record audit findings in Vendor Audit Log (Annexure-4).

6. CAPA Management
Require CAPA plans for all critical and major audit findings.
Track CAPA implementation and closure timelines.
Document CAPA details in CAPA Log (Annexure-5).

7. Escalation
Escalate repeated non-compliance, critical GCP violations, or data integrity concerns.
Document escalations in Vendor Escalation Log (Annexure-6).

8. Termination of Vendor Engagement
If vendor fails to comply, initiate termination process per contract.
Ensure transfer of data, documents, and responsibilities to new vendor or sponsor team.

9. Documentation and Archiving
Archive vendor qualification, contracts, performance logs, audit reports, CAPA records, and governance minutes in TMF.
Retain documents for at least 15 years or as per jurisdiction.

Abbreviations

• SOP: Standard Operating Procedure
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• KPI: Key Performance Indicator
• SLA: Service Level Agreement
• CAPA: Corrective and Preventive Action

Documents

1. Vendor Qualification Log (Annexure-1)
2. Vendor Oversight Plan (Annexure-2)
3. Vendor Performance Log (Annexure-3)
4. Vendor Audit Log (Annexure-4)
5. CAPA Log (Annexure-5)
6. Vendor Escalation Log (Annexure-6)

References

• ICH E6(R2) – Good Clinical Practice
• FDA – Oversight of Clinical Investigations
• EMA – Clinical Vendor Oversight Guidance
• CDSCO – Vendor Oversight in Clinical Trials
• WHO – Clinical Research Governance Guidelines

Version: 1.0

Approval Section

Prepared By	Ravi Kumar, Vendor Manager
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head Clinical Operations

Annexures

Annexure-1: Vendor Qualification Log

Date	Vendor	Service	Qualification Outcome	Reviewer
10/09/2025	ABC Labs	Bioanalysis	Qualified	QA Officer
12/09/2025	XYZ CRO	Monitoring	Qualified	Sponsor

Annexure-2: Vendor Oversight Plan

Vendor	Communication Frequency	KPIs	Oversight Contact
ABC Labs	Monthly	Turnaround time, accuracy	Vendor Manager
XYZ CRO	Quarterly	Monitoring timeliness, deviation closure	Clinical Ops Manager

Annexure-3: Vendor Performance Log

Date	Vendor	Deliverable	Performance	Reviewer
14/09/2025	ABC Labs	Lab reports	98% accuracy	QA Officer
16/09/2025	XYZ CRO	MVR submission	Delayed by 2 days	Sponsor

Annexure-4: Vendor Audit Log

Date	Vendor	Audit Scope	Findings	Reviewer
18/09/2025	ABC Labs	Data integrity	Minor deviation	QA Officer
19/09/2025	XYZ CRO	Monitoring SOPs	No findings	Sponsor

Annexure-5: CAPA Log

Date	Vendor	Issue	CAPA	Status
20/09/2025	ABC Labs	Delayed reports	Implemented escalation alert	Closed
21/09/2025	XYZ CRO	Monitoring delay	Additional staff assigned	Open

Annexure-6: Vendor Escalation Log

Date	Vendor	Issue	Escalated To	Resolution
22/09/2025	ABC Labs	Data discrepancy	Sponsor	Under review
23/09/2025	XYZ CRO	Repeated delays	Clinical Ops Manager	Corrective training

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head, Clinical Operations

For more SOPs visit: Pharma SOP